Abstract
Psychiatry is a specialty where the application of pharmacogenomics approaches is made to the study of interindividual differences in response to antidepressants. It is highly applied for improving patient treatment. Major depressive disorder (MDD) is a common and complex disorder resulting from genetic and environmental interactions. Less than 40% of patients with MDD achieve remission, and even after several treatment trials, one in three patients do not fully recover from MDD. Many clinical and genomic association studies suggested that the catechol-Omethyltransferase (COMT) gene region was an important genetic locus for psychiatric disorders, because of the proposed relationship between its function in catecholaminergic neurotransmission and individual response to antidepressants, and vulnerability to psychiatric disorders. Although a number of COMT single nucleotide polymorphisms (SNPs) were observed, the Val108/158Met (rs4680) polymorphism in exon 4 resulted in a change in the enzyme structure which has been intensively investigated in relation to its role of enzyme activity and processes of prefrontal cortex functions in cognition. As serotonin interacts with dopamine and dopamine availability is influenced by COMT SNPs, an association between the COMT gene and response to treatment, based on the various pharmacogenetics/pharmacogenomics studies about COMT gene published to date, is explored in this overview.
Keywords: COMT gene, pharmacogenetics, antidepressant, treatment response, snp, Catechol O Methyl Transferase, Major Depressive disorder , COMT, MDD, rs4680, Antidepressant treatment, Dopamine
CNS & Neurological Disorders - Drug Targets
Title:Catechol-O-Methyltransferase (COMT) Pharmacogenetics in the Treatment Response Phenotypes of Major Depressive Disorder (MDD)
Volume: 11 Issue: 3
Author(s): Neslihan Aygun Kocabas
Affiliation:
Keywords: COMT gene, pharmacogenetics, antidepressant, treatment response, snp, Catechol O Methyl Transferase, Major Depressive disorder , COMT, MDD, rs4680, Antidepressant treatment, Dopamine
Abstract: Psychiatry is a specialty where the application of pharmacogenomics approaches is made to the study of interindividual differences in response to antidepressants. It is highly applied for improving patient treatment. Major depressive disorder (MDD) is a common and complex disorder resulting from genetic and environmental interactions. Less than 40% of patients with MDD achieve remission, and even after several treatment trials, one in three patients do not fully recover from MDD. Many clinical and genomic association studies suggested that the catechol-Omethyltransferase (COMT) gene region was an important genetic locus for psychiatric disorders, because of the proposed relationship between its function in catecholaminergic neurotransmission and individual response to antidepressants, and vulnerability to psychiatric disorders. Although a number of COMT single nucleotide polymorphisms (SNPs) were observed, the Val108/158Met (rs4680) polymorphism in exon 4 resulted in a change in the enzyme structure which has been intensively investigated in relation to its role of enzyme activity and processes of prefrontal cortex functions in cognition. As serotonin interacts with dopamine and dopamine availability is influenced by COMT SNPs, an association between the COMT gene and response to treatment, based on the various pharmacogenetics/pharmacogenomics studies about COMT gene published to date, is explored in this overview.
Export Options
About this article
Cite this article as:
Aygun Kocabas Neslihan, Catechol-O-Methyltransferase (COMT) Pharmacogenetics in the Treatment Response Phenotypes of Major Depressive Disorder (MDD), CNS & Neurological Disorders - Drug Targets 2012; 11 (3) . https://dx.doi.org/10.2174/187152712800672445
DOI https://dx.doi.org/10.2174/187152712800672445 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Forgotten Cells: Role of Astrocytes in Mood Disorders During the Aging
Current Neuropharmacology Colchicine Protects Dopaminergic Neurons in a Rat Model of Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Development of Meat and Poultry Products Enriched with n-3 PUFAs and their Functional Role
Current Nutrition & Food Science Machine Learning Approaches for Cognitive State Classification and Brain Activity Prediction: A Survey
Current Bioinformatics Recent Knowledge on Molecular Components of Lewy Bodies Discloses Future Therapeutic Strategies in Parkinsons Disease
Current Drug Targets - CNS & Neurological Disorders Pain and Child: A Translational Hypothesis on the Pathophysiology of a Mild Type-2 Diabetes Model
Endocrine, Metabolic & Immune Disorders - Drug Targets Castor Oil Based Multifunctional Greener Additives for Lubricating Oil
Current Environmental Engineering P-Glycoprotein and Breast Cancer Resistance Protein Affect Disposition of Tandutinib, A Tyrosine Kinase Inhibitor
Drug Metabolism Letters Cerebral Artery Signal Transduction Mechanisms: Developmental Changes in Dynamics and Ca<sup>2+</sup> Sensitivity
Current Vascular Pharmacology Child Welfare in Japan: Children’s Care Homes and Mental Health
Adolescent Psychiatry Postmenopausal Hypertension: Insights from Rat Models
Current Hypertension Reviews Study on the Development of a Cyclohexane Based Tripodal Molecular Device as "OFF-ON-OFF" pH Sensor and Fluorescent Iron Sensor
Current Analytical Chemistry α/βHydrolase Fold: An Update
Protein & Peptide Letters Erythropoietin Gene Polymorphism rs551238 is Associated with a Reduced Susceptibility to Brain Injury in Preterm Infants
Current Neurovascular Research Software Implementation of BeiDou B1I Code Generator Using Matlab/Simulink
Recent Patents on Computer Science Histamine H<sub>4</sub> Receptor Antagonists: A New Approach for Tinnitus Treatment?
Recent Patents on CNS Drug Discovery (Discontinued) Binding Model of Capsaicin is Able to Reach the Peripheral Anionic Site of Acetylcholinesterase
Current Bioactive Compounds The Fall in Older Adults: Physical and Cognitive Problems
Current Aging Science Conceptualizing Excessive Behaviour Syndromes: A Systematic Review
Current Psychiatry Reviews Chronic Inflammation and Cancer: The Role of Endothelial Dysfunction and Vascular Inflammation
Current Pharmaceutical Design